A Microarray Platform-Independent Classification Tool for Cell of Origin Class Allows Comparative Analysis of Gene Expression in Diffuse Large B-cell Lymphoma-Reference-Cited by-同舟云学术

A Microarray Platform-Independent Classification Tool for Cell of Origin Class Allows Comparative Analysis of Gene Expression in Diffuse Large B-cell Lymphoma

Published:2013-02-12 Issue:2 Volume:8 Page:e55895
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Care Matthew A.,Barrans Sharon,Worrillow Lisa,Jack Andrew,Westhead David R.,Tooze Reuben M.

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference64 articles.

1. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling;AA Alizadeh;Nature,2000

2. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma;G Wright;Proc Natl Acad Sci U S A,2003

3. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma;A Rosenwald;N Engl J Med,2002

4. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways;G Lenz;Proc Natl Acad Sci U S A,2008

5. Stromal gene signatures in large-B-cell lymphomas;G Lenz;The New England journal of medicine,2008

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Skeletal muscle of young females under resistance exercise exhibits a unique innate immune cell infiltration profile compared to males and elderly individuals;Journal of Muscle Research and Cell Motility;2024-04-05

2. Prognostic implications of cGAS and STING gene expression in acute myeloid leukemia;Experimental Biology and Medicine;2024-02-29

3. Comparison of Machine Learning Classifiers on Integrated Transcriptomic Data;2023 IEEE International Conference on Big Data (BigData);2023-12-15

4. Elraglusib (formerly 9-ING-41) possesses potent anti-lymphoma properties which cannot be attributed to GSK3 inhibition;Cell Communication and Signaling;2023-06-14

5. Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up;Journal of Clinical Oncology;2023-05-20